PSP
APTO

Principal Street Partners’s Aptose Biosciences, Inc. APTO Stock Holding History

Principal Street Partners’s Portfolio APTO Stock Details APTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-48
Closed -$72K – 203
2021
Q2 		$72K Sell
48
-11
-19% -$24K 0.02% 207
2021
Q1 		$159K Buy
+59
New +$117K 0.02% 186

Other funds holding APTO

DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return

Principal Street Partners's APTO Position: Q3 2021 in Review

Principal Street Partners sold out of Aptose Biosciences, Inc. (APTO) in Q3 2021, closing a stake of 48 shares — an estimated $72K sold.

Principal Street Partners first reported a position in APTO in Q1 2021 and held it in 2 quarters. The position peaked at $159K in Q1 2021. 64 funds tracked by Wall St. Rank hold APTO as of Q3 2021.

  • Principal Street Partners reported no remaining Aptose Biosciences, Inc. position as of Q3 2021 after selling out during the quarter.
  • Principal Street Partners sold 48 Aptose Biosciences, Inc. shares in Q3 2021, an estimated $72K.
  • Principal Street Partners first reported a position in Aptose Biosciences, Inc. in Q1 2021 and held it in 2 quarters.
  • Principal Street Partners's Aptose Biosciences, Inc. position peaked at $159K in Q1 2021.
  • 64 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q3 2021.

Based on Principal Street Partners's 13F filing for Q3 2021, filed 10 Nov 2021.